AS

Astrana Health, Inc.

ASTHHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.18B
+56.4% YoY
Net Income
$22.5M
-47.9% YoY
EBITDA
$135.3M
-4.6% YoY
Free Cash Flow
$231.2M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 19 MACD Positive CrossoverHistogram +0.5477, positive momentum
Aug 18 MACD Positive CrossoverHistogram +0.4987, positive momentum
About Astrana Health, Inc.

Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company carries a $1.91B market cap, placing it firmly in the small-cap category. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.

Where ASTH stands vs its 150-day and 200-day moving averages

As of the August 19, 2026 close, ASTH finished 20.16% above its 150-day moving average ($32.59) and 27.81% above its 200-day moving average ($30.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is ASTH overbought or oversold?

At the August 19, 2026 close, ASTH's RSI(14) was 57.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.91B
P/E (TTM)46.91
Fwd P/E10.87
EPS$0.82
Beta0.91
52W Change+30.4%
ROE6.9%
Analysis

On the balance sheet, ASTH has $400.8M in cash with $979.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $231.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 6.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.14B (2022) to $3.18B (2025), reflecting a 178% increase over the period.

Investors considering Astrana Health, Inc. should weigh the typical risks associated with ASTH's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ASTH.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms